↓ Skip to main content

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

Overview of attention for article published in BMC Medicine, April 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

policy
1 policy source
twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
75 Dimensions

Readers on

mendeley
64 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
Published in
BMC Medicine, April 2017
DOI 10.1186/s12916-017-0831-7
Pubmed ID
Authors

Marion Savina, Axel Le Cesne, Jean-Yves Blay, Isabelle Ray-Coquard, Olivier Mir, Maud Toulmonde, Sophie Cousin, Philippe Terrier, Dominique Ranchere-Vince, Pierre Meeus, Eberhard Stoeckle, Charles Honoré, Paul Sargos, Marie-Pierre Sunyach, Cécile Le Péchoux, Antoine Giraud, Carine Bellera, François Le Loarer, Antoine Italiano

Abstract

Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals. The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group were analyzed. The median number of systemic treatments was 3 (range, 1-6); 27% of the patients did not receive any systemic treatment and 1054 (49%) patients underwent locoregional treatment of the metastasis. Half of the patients who underwent chemotherapy (n = 810) received an off-label drug. Leiomyosarcoma was associated with a significantly better outcome than the other histological subtypes. With the exception of leiomyosarcomas, the benefit of a greater than third-line regimen was very limited, with a median time to next treatment (TNT) and overall survival (OS) ranging between 2.3 and 3.7 months and 5.4 and 8.5 months, respectively. The TNT was highly correlated with OS. Female sex, leiomyosarcoma histology, locoregional treatment of metastases, inclusion in a clinical trial, and treatment with first-line polychemotherapy were significantly associated with improved OS in the multivariate analysis. The combination of doxorubicin with a second drug, such as ifosfamide, represents a valid option, particularly when tumor shrinkage is expected to provide clinical benefits. After failure of the second-line therapy, best supportive care should be considered, particularly in patients with non-leiomyosarcoma histology who are not eligible to participate in a clinical trial. Locoregional treatment of metastasis should always be included in the therapeutic strategy when feasible. TNT may represent a useful surrogate endpoint for OS in clinical studies.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 16%
Student > Ph. D. Student 8 13%
Other 6 9%
Student > Doctoral Student 6 9%
Student > Postgraduate 5 8%
Other 12 19%
Unknown 17 27%
Readers by discipline Count As %
Medicine and Dentistry 30 47%
Biochemistry, Genetics and Molecular Biology 3 5%
Psychology 3 5%
Nursing and Health Professions 2 3%
Agricultural and Biological Sciences 2 3%
Other 3 5%
Unknown 21 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2021.
All research outputs
#5,038,331
of 19,026,578 outputs
Outputs from BMC Medicine
#2,001
of 2,853 outputs
Outputs of similar age
#85,616
of 277,117 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 19,026,578 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,853 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.4. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,117 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them